Boehringer Ingelheim and 3T announce second cancer immunotherapy partnership

08 Jan 2024
www.pmlive.com
License out/inImmunotherapy
Boehringer Ingelheim and 3T announce second cancer immunotherapy partnership
Preview
Source: PMLiVE
Boehringer Ingelheim and 3T Biosciences have announced a second partnership aimed at developing next-generation cancer immunotherapies, bringing the potential milestone payments of the agreements up to $538.5m.
The new strategic collaboration and licensing deal builds on the "successful completion" of the companies' initial oncology research partnership, they said.
Announced in January last year, the agreement saw Boehringer input its patient-derived T-cell receptor (TCR) data into 3T’s discovery platform, 3T TRACE, with the aim of identifying novel antigen targets for cancer immunotherapies.
3T’s platform is designed to improve the identification of novel shared TCR targets and screening of TCRs by combining high-diversity target libraries with active machine learning, potentially leading to tumour-specific, safer therapies that can be delivered at higher doses.
Under the latest deal, Boehringer will once again provide TCR data to support the immunotherapy company’s target discovery efforts to identify antigens.
In exchange, 3T will receive an undisclosed upfront payment and research and development support from Boehringer and will be eligible for milestone payments for both agreements totalling $538.5m, as well as royalties on future Boehringer product sales.
Boehringer will also be eligible to receive royalties on future product sales by 3T arising from the agreement, the companies outlined.
Lamine Mbow, global head of cancer immunology and immune modulation at Boehringer, said: "The initial success of our work with 3T gives us confidence that together we can and will expand and accelerate our pipeline of first-in-class T-cell based anti-cancer therapies."
Stefan Scherer, 3T’s president and chief executive officer, added that the work the companies have done over the past year “provides a higher degree of validation of [its] 3T-TRACE discovery platform”.
“Based on the success of this initial work, we will now go broader and deeper into other cancers,” he said.
The announcement came just one day after Boehringer said it had partnered with China-based Suzhou Ribo Life Science and its Swedish unit Ribocure Pharmaceuticals to develop new treatments for liver diseases, with the deal potentially worth over $2bn.
The multi-target collaboration is specifically aimed at developing treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.